Cartesian Therapeutics reported a quarterly loss of $1.46 per share, missing the Zacks Consensus Estimate for a $0.84 loss by $0.62 per share. The loss also widened from $0.68 per share in the year-ago quarter, indicating deterioration in profitability. The update is negative for near-term sentiment but is likely to have a stock-specific rather than sector-wide impact.
Cartesian Therapeutics reported a quarterly loss of $1.46 per share, missing the Zacks Consensus Estimate for a $0.84 loss by $0.62 per share. The loss also widened from $0.68 per share in the year-ago quarter, indicating deterioration in profitability. The update is negative for near-term sentiment but is likely to have a stock-specific rather than sector-wide impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
